Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HDM1002 in Chinese Overweight and Obese Adults
NCT06520540Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- Jul 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of conveglipron in Overweight and obesity (4 arms), sponsored by Huadong Medicine. Primary endpoint: Treatment-Emergent Adverse Events at Week 12. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
conveglipron
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06520540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520540.